Skip to main navigation Skip to search Skip to main content

CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)

  • Brad S. Kahl
  • , Krzysztof Giannopoulos
  • , Wojciech Jurczak
  • , Martin Šimkovič
  • , Mazyar Shadman
  • , Anders Österborg
  • , Luca Laurenti
  • , Patricia Walker
  • , Stephen Opat
  • , Henry Chan
  • , Hanna Ciepluch
  • , Richard Greil
  • , Monica Tani
  • , Marek Trnéný
  • , Danielle M. Brander
  • , Ian W. Flinn
  • , Sebastian Grosicki
  • , Emma Verner
  • , Jennifer R. Brown
  • , Paolo Ghia
    • Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Tadeusz Robak, Peter Hillmen, Constantine S. Tam

Research output: Contribution to journal › Article › peer-review

4   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science